Related Experiment Videos
Drug-induced lupus erythematosus
Piercarlo Sarzi-Puttini1, Fabiola Atzeni, Franco Capsoni
1Department of Rheumatology, Rheumatology Unit, L Sacco University Hospital, via GB Grassi 74, Milan 20157, Italy. sarzi@hotmail.com
Autoimmunity
|December 24, 2005
Summary
Drug-induced lupus erythematosus (DILE) mimics idiopathic lupus but arises from medications. Recognizing DILE is crucial as symptoms typically resolve after discontinuing the causative drug.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Drug-induced lupus erythematosus (DILE) is a condition sharing clinical and laboratory features with idiopathic systemic lupus erythematosus (SLE).
- Over 80 drugs have been linked to DILE, with distinct demographic profiles compared to idiopathic SLE (e.g., older average age, lower female prevalence).
Purpose of the Study:
- To review general aspects of DILE, including pathogenic mechanisms, clinical presentations, and diagnostic criteria.
- To provide updated information on recently implicated drugs such as minocycline, statins, and anti-TNF-alpha agents.
Main Methods:
- Literature review of drug-induced lupus erythematosus.
- Analysis of historical cases and recent drug associations.
- Synthesis of information on pathogenesis, clinical forms, and diagnostics.
Main Results:
- DILE presents with symptoms like arthralgia, myalgia, rash, and fever, often with positive antinuclear antibodies.
- Unlike idiopathic SLE, central nervous system and renal involvement are uncommon in DILE.
- DILE typically resolves within weeks of drug cessation.
Conclusions:
- DILE is a significant clinical entity that requires recognition for prompt management.
- Early identification and discontinuation of the offending agent are key to favorable outcomes in drug-induced lupus.